Moxifloxacin HCL cas 186826-86-8

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent. Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."

Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.

Related Prodcuts:

Moxifloxacin; Fasudil; Fasudil HCL; Pixantrone Maleate; Topotecan Hydrochloride; Irinotecan HCl Trihydrate; Irinotecan; Gemfibrozil; Cicloheximide; Oxaliplatin; Camptothecin; 10-Hydroxycamptothecin; Bendamustine hydrochloride

[1]. Balfour, J.A. and H.M. Lamb, Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs, 2000. 59(1): p. 115-39.

[2]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.